The Siglecs (sialic acid-binding Ig-like lectins) are a subfamily of I-type lectins, which specifically recognize sialic acids. Nine members of the family have been identified thus far. We have obtained a novel cDNA clone from a human dendritic cell cDNA library encoding a protein with sequence and structural features of the Siglec family, hence designated as Siglec-10. The fulllength Siglec-10 cDNA encodes a type 1 transmembrane protein containing four extracellular immunoglobulinlike domains, a transmembrane region, and a cytoplasmic tail with two classical immunoreceptor tyrosinebased inhibitory motifs. The N-terminal V-set Ig domain has most of the amino acid residues typical of the Siglecs. Siglec-10 shows the closest homology to Siglec-5 and Siglec-3/CD33. Various cells and cell lines including monocytes and dendritic cells express Siglec-10. High levels of mRNA expression were seen in peripheral blood leukocytes, spleen, and liver. When expressed on COS-7 cells, Siglec-10 was able to bind human red blood cells and soluble sialoglycoconjugates in a sialic acid-dependent manner. The identification of Siglec-10 as a new Siglec family member and its expression profile, together with its sialic acid-dependent binding capacity, suggest that it may be involved in cell-cell recognition by interacting with sialylated ligands expressed on specific cell populations.
The Siglec (sialic acid-binding Ig-like lectins) 1 family is a subset of structurally related Ig superfamily (IgSF) proteins that mediates protein-carbohydrate interactions, specifically recognizing sialic acid in oligosaccharide chains of glycoproteins and glycolipids. The family currently comprises nine members in humans: Siglec-1/sialoadhesin (1), Siglec-2/CD22 (2), Siglec-3/CD33 (3), Siglec-4a/myelin-associated glycoprotein (4), Siglec-5 (5), Siglec-6/OBBP-1 (6), Siglec-7/AIRM1 (7-9), Siglec-8/SAF-2 (10, 11) , and Siglec-9 (12) (13) (14) . Each member of the family is expressed by specific cell types and has a particular preference for both the nature of sialic acid binding and the glycosidic linkage to adjacent sugars (4, 16) .
The Siglecs are all single-pass type 1 transmembrane polypeptides with an N-terminal Ig V-set domain followed by variable numbers of downstream C2-set domains ranging from one in CD33 to 16 in sialoadhesin. All Siglecs also possess a transmembrane domain and cytoplasmic tail. It has been established that the first V-set Ig-like domain is the most important in carbohydrate recognition and that the second Ig-like domain may also contribute to the binding (17) (18) (19) (20) . In particular, a conserved arginine on the F-strand of the V-set domain is essential for sialic acid-dependent binding by all Siglecs (19 -21) . Other conserved residues include aromatic amino acids on the A and G ␤-strands of the V-set domain that contact the N-acetyl and glycerol side group of N-acetyl neuraminic acid (22) . All Siglecs characterized have an unusual arrangement of conserved cysteine residues in the V-set and adjacent C2-set domains (23) , resulting in the formation of an intrasheet disulfide bond in the N-terminal V-set domain and an interdomain disulfide bond between the V-set domain and the proximal C2-set domain (22, 24) .
Many of the Siglecs have potential tyrosine phosphorylation sites in the context of an immunoreceptor tyrosine-based inhibitory motif (ITIM) in their cytoplasmic tails, suggesting their involvement in intracellular signaling pathways. Recently, a growing number of leukocyte membrane receptors have been described to contain at least one ITIM motif. Such ITIM motifs, when tyrosine-phosphorylated, have been shown to mediate negative regulatory signals via the recruitment and activation of intracellular phosphatases (SHP-1, SHP-2, or SH2 domain-containing inositol phosphatase) (25) . It has been reported that CD33/Siglec-3 and Siglec-7 are capable of transmitting negative regulatory signals upon cross-linking by specific antibodies (7, 26, 27) . Knockout studies of CD22/Siglec-2 have demonstrated that it is a negative regulator of B cell activation (28 -31) .
In this study we report the molecular cloning and characterization of a new member of Siglec family from human dendritic cells (DCs) designated Siglec-10. The protein shares high homology with Siglec-5, CD33/Siglec-3, and other Siglec members and possesses all of the key structural features of the Siglecs described above. Like other Siglec members, Siglec-10 is able to mediate sialic acid-dependent binding to cells either when expressed on COS-7 cells or as a recombinant fusion protein immobilized on plastic. In addition, we have examined the cell and tissue expression of Siglec-10, which revealed its expression in a large number of cells and tissues including human DCs and monocytes.
EXPERIMENTAL PROCEDURES
Materials-Unless otherwise specified, all reagents were purchased from Sigma. Culture media were obtained from Life Technologies, Inc. Vibrio cholerae sialidase was purchased from Calbiochem. [ 125 I]-Streptavidin (20 -40 mCi/mg) was purchased from Amersham Pharmacia Biotech. A cDNA encoding full-length dendritic cell-derived IFNinduced protein (DCIP) in the pSPORT vector was obtained from a human DC cDNA library produced in our laboratory. Biotinylated polyacrylamide (PAA) carrying either NeuAc␣2,3Gal␤1,4Glc (2,3-PAA) or NeuAc␣2,6Gal␤1,4Glc (2,6-PAA) was purchased from Syntesome (Munich, Germany).
Isolation of Siglec-10 cDNA-The full-length cDNA of Siglec-10 was directly isolated from a cDNA library of human DCs by random sequencing as described previously (31) . Briefly, DCs were derived from human peripheral monocytes by culture with granulocyte/macrophage colony-stimulating factor and interleukin (IL)-4 and enriched by a CD1a-mediated positive selection at day 7 of culture. A plasmid cDNA library of pSPORT vector was constructed using the Superscript TM plasmid system for cDNA synthesis. Plasmid cloning was performed according to manufacturer instructions (Life Technologies, Inc.). By large-scale sequencing of the DC cDNA library, we established an in-house data base of 25,668 expressed sequence tags, based on which more than 100 full-length novel genes have been isolated. The fulllength cDNA of clone SBBI91 was found to potentially encode a protein with an Ig domain sharing homology with the known Siglecs, hence designated as Siglec-10. The full-length sequence is available in the GenBank TM data base with accession number AF311905. TM accession numbers for CD33 (Siglec-3), Siglec-5, -6, -7, -8, -9, and -10 are M23197, AF170484, D86358, AF170485, NM 014442, AF247180, and AF311905, respectively. days in the presence of granulocyte/macrophage colony-stimulating factor and IL-4 were further cultured in the presence of LPS (100 g/ml).
Siglec-10 mRNA Expression Analysis by RT-PCR and Northern blot Analysis-Total cellular RNA was isolated using Trizol reagent (Life Technologies, Inc.) according to manufacturer instructions, and first strand cDNA was prepared with the Superscript II system using an oligo(dT) [12] [13] [14] [15] [16] [17] [18] primer. The synthesis of cDNA was checked by RT-PCR using ␤-actin primers. RT-PCRs with the primers 5Ј-TGGCTCA-GAAGCGGAATC-3Ј (forward) and 5Ј-CCTCATTGGAACTTGACT-TCTGC-3Ј (backward) specific for Siglec-10 cDNA were subjected to denaturing (95°C for 15 s), annealing (57°C for 30 s), and extension (72°C for 30 s) for 28 cycles using a Perkin-Elmer GeneAmp PCR System 9600.
Human adult multiple tissue Northern blots (CLONTECH) were used to detect mRNA expression by Northern blot analysis. The RT-PCR products mentioned above were cloned into a T/A vector for sequencing and labeled by random priming with [␣-32 P]dCTP (50 Ci, 3000 Ci/mmol, Amersham Pharmacia Biotech) as a probe. Unincorporated nucleotides were removed by spin column chromatography (Roche Molecualr Biochemicals). Hybridization was performed in Express Hyb TM hybridization solution (CLONTECH) according to manufacturer instructions. After stringently washing at 50°C for 20 min in 0.1ϫ SSC and 0.1% SDS, the filters were subjected to autoradiography.
Production of Recombinant Chimeric Siglec-10-Fc Protein-A cDNA fragment of Siglec-10 encoding the extracellular Ig-like domains was amplified by PCR using forward (5Ј-ACGAATTCTGCGCCTCCTAT-GCGGAGAT G-3Ј) and reverse (5Ј-GCGGATCCCCGTTGGAGAATGC-CGTTGAG-3Ј) primers from DC cDNA as a template. The fragment was cloned into the expression vector pcDNA-3.1-Fc, giving rise to a fusion protein of Siglec-10 extracellular domains and a human IgG Fc tail. The constructs were transfected using LipofectAMINE reagent (Life Technologies, Inc.) into COS-7 cells, the culture supernatants were collected, and the chimeric proteins were purified on protein A-Sepharose (Amersham Pharmacia Biotech).
Red Blood Cell Binding Assays-These were carried out as described previously (4) . Briefly, COS-7 cells were sham-transfected or transfected using LipofectAMINE with cDNA encoding full-length Siglec-10 or Siglec-5 used as a positive control (obtained from a human DC cDNA library produced in our laboratory). Erythrocyte rosetting was performed 48 h after transfection with or without sialidase pretreatment of COS-7 cells or erythrocytes and assessed by microscopy after a thorough washing to remove unbound red blood cells. A solid-phase binding assay with human RBCs was performed as described previously with the Siglec-10-Fc fusion protein (4) .
Binding Assays with Polyacrylamide Glycoconjugates-COS-7 cells were transfected with full-length cDNAs encoding Siglec-10, Siglec-5, or DCIP as a mock control, and binding assays were carried out 60 h later. The COS-7 cells were either left untreated or treated with 0.1 units/ml sialidase for 2 h at 37°C. The cells were incubated with saturating concentrations (20 g/ml) of 2,3-PAA or 2,6-PAA for 1 h at room temperature, washed in PBA (PBS containing 0.25% bovine serum albumin), and incubated with [ 125 I]-streptavidin diluted to 0.5 Ci/ml in PBA for 1 h at 4°C. After washing in PBA, bound radioactivity was counted using a Wallac gamma counter. 
FIG. 3. Phylogenetic analysis of the Siglec family.
The first 1000 nucleotides of Siglecs were aligned to create the phylogenetic tree using ClustalW (35) and TreeView (36) . The scale bar indicates the number of substitutions per site. Siglec-10 is closely related to CD33, Siglec-5, and Siglec-6 and is more distantly related to other Siglecs.
RESULTS
Identification of Siglec-10 and Sequence Analysis-The 3124-base pair full-length clone directly isolated from the human DC cDNA library encoded a type I transmembrane protein of 602 amino acids belonging to the IgSF. A BLAST search with the amino acid sequence detected similarities to other Siglec family members. At the primary sequence level, it most closely resembled Siglec-5 (overall sequence 51% similarity and 38% identity, Fig. 1 ). Based on its sequence similarity with other Siglecs, the conservation of Siglec features, and its capacity of sialic acid-dependent binding (shown below), the protein was designated as Siglec-10 ( Fig. 1) . The extracellular region of Siglec-10 contains a hydrophobic signal peptide and four Ig-like domains (one V-set domain followed by three C2-set domains). There were three putative N-glycosylation sites in the extracellular region including one highly conserved site at position 100 (20) . The transmembrane region comprised position 453-479, after which was a cytoplasmic tail of 123 amino acids (Fig. 1) .
Structural Features Characteristic of Siglecs in Siglec-10 -The N-terminal Ig-like domains contained many structural features of the Siglec subgroup of IgSF (Fig. 2) . Previously demonstrated conservation of the unusual pattern of cysteines was found in Siglec-10, particularly the cysteines on the B-and E-strands of domain 1, which are thought to result in an intrasheet disulfide bond (22) , and the cysteines on the A-B loop of domain 1 and the B-C loop of domain 2, which may give rise to an interdomain disulfide bond (24) . Conversation of other key amino acids included a typically placed arginine (Arg-119). Also, two aromatic amino acids (Phe-21 and Phe-130) on the Aand G-strands of the V-set domain were present, both of which are known to be involved in sialic acid binding of Siglec-1/ sialoadhesin from x-ray crystallographic analysis (22) and of Siglec-1, -2, -3, -4, and -7 by mutagenesis experiments (9, 19 -21, 26) .
Homology of individual Ig-like domains was compared with those of other Siglecs. In the first two extracellular domains, Siglec-10 is most similar to the two extracellular domains of CD33 (65% similarity and 48% identity), whereas the third Ig domain most closely resembles the Siglec-7 domain 3 (57% similarity and 42% identity). The fourth Ig domain is most similar to Siglec-8 Ig domain 3, with high similarity of up to 73% and 60% identity. Alignment of the intracellular domain of Siglec-10 with other Siglecs revealed a high degree of sequence identity and similarity to CD33/Siglec-3.
Notably, the four Ig-like domains of Siglec-10 contained three, three, two, and three cysteines, respectively, suggesting that there might be either interdomain disulfide bonds as for other Siglecs or interpolypeptide disulfide bonds as in Igs. Within the putative cytoplasmic tail were four tyrosine residues (Fig. 2) , of which the first (Tyr-502) and third (Tyr-572) have been identified in the immunoreceptor tyrosine-based inhibitory motif (ITIM, S/I/L/VXYXXL/V). The two motifs (LDYINV and LHYATL) conformed well to the consensus ITIM that has been found in several other leukocyte proteins. Alignment of the closely related Siglec subset (Siglec-5, -6, -7, and -9; Fig. 1 ) reveals a low degree of conservation in the cytoplasmic tail except for the amino acids surrounding two tyrosines in the ITIM and the ITIM-like motifs. The two ITIM motifs of Siglec-10 were not, however, found at the corresponding sites of other Siglecs. Despite the site differences, the presence of ITIM motifs suggests that the motifs are under functional positive selection. The fourth tyrosine residue (membrane distal, Tyr-596) did not conform to the ITIM motif but is similar to the membrane-distal ITIM-like motif characterized in some other leukocyte receptors (33, 34) .
Phylogenetic analysis of the entire Siglec family (Fig. 3) was performed by the ClustalW (35) and TreeView (36) programs. The results revealed a close association between Siglec-10 and CD33, Siglec-6, and Siglec-5 as expected from the high sequence identity mentioned above. The novel gene, encoding the Siglec-10 protein, possesses all the necessary features, such as the Ig-like domains, the type-I transmembrane topology, and the conserved cytoplasmic motifs, for it to be designated as the newest member of the Siglec family. It also shows a close phylogenetic relationship to the other Siglec family members.
Expression Patterns of Siglec-10 -By RT-PCR we have demonstrated the mRNA expression of Siglec-10 in a large number of cells including HL60 (myelomonocytic), U937 (promonocytic), THP-1 (monocytic), MOLT-4 (T lymphoma), Raji (B lymphoma), MCF-7 (breast adenocarcinoma), PC-3 (prostate ade- Characterization of Siglec-10nocarcinoma), A172 (glioblastoma), SMMC 7721 (hepatoma), HeLa (cervical adenocarcinoma), A549 (lung carcinoma), and freshly isolated human peripheral monocytes (Fig. 4A) . No message was detected in K562 (erythroid/megakaryocytic), LoVo (colorectal adenocarcinoma), HT-29 (colorectal adenocarcinoma), or CaoV-3 (ovarian adenocarcinoma) cells. We also examined the effect of LPS stimulation on Siglec-10 expression in human DCs. DCs derived from peripheral monocytes cultured in the presence of granulocyte/macrophage colony-stimulating factor and IL-4 expressed Siglec-10 at relatively high levels before LPS stimulation. The expression decreased after the stimulation with LPS, reaching a minimum at 24 h, and increased again to a high level after 48 h of stimulation (Fig.  4B) . These results suggested that DCs expressed Siglec-10 in a time-dependent manner after the activation with LPS.
The mRNA expression pattern of Siglec-10 in human tissues was examined by Northern blot analysis (Fig. 5) . Because the first three Ig-like domains of Siglec-10 were of high similarity to other Siglecs, we designed a probe to minimize the likelihood of cross-reactivity and performed hybridization under stringent conditions. Two major forms of transcripts were observed. The larger one was ϳ3.3 kilobases in length and was found in peripheral blood lymphocytes, ovary, and spleen; therefore, the 3124-base pair cDNA isolated from DCs is likely to represent a full-length mRNA. The other transcript was estimated to be ϳ1.8 kilobases in length and was present in liver, spleen, thymus, and lung. This is likely to represent alternatively spliced mRNA rather than different gene family members based on the low cross-reactivity of the probe and the stringency of conditions used. RBCs were added. Both Siglec-10-and Siglec-5-transfected COS-7 cells bound RBCs at a moderate level. Notably, sialidase pre-treatment of COS-7 cells that could eliminate sialylated ligands on the same cell surface (cis-ligands) augmented RBC adhesion by at least 50% (Fig. 6, A and B) . In all cases, this binding was completely abrogated by sialidase pretreatment of RBCs, indicating that the binding is sialic acid-dependent. In a solid-phase binding assay, the Siglec-10-Fc fusion protein containing the extracellular domains of Siglec-10 was able to bind RBCs at a high level, and this binding was also eliminated completely by sialidase pretreatment of RBCs (data not shown). The results suggested that, just as with other Siglecs, the recognition function of Siglec-10 could be masked and hence regulated by endogenous sialylation on the same cell surface.
To determine the sialic acid linkage preference of Siglec-10, COS-7 cells were transiently transfected with cDNAs encoding Siglec-10, Siglec-5 as a positive control, or DCIP as a mock control. After sialidase treatment of the COS-7 cells to remove potentially cis-inhibitory sialic acids, binding assays were carried out using biotinylated polyacrylamide, derivatized with 3Ј-or 6Ј-sialyllactose (Fig. 7) . Under these conditions, untransfected wild-type COS-7 cells showed no detectable binding to glycoconjugates. With sialidase-treated COS-7 cells, the property of Siglec-10 was more similar to that of Siglec-5, binding glycoconjugates carrying sialic acid in either ␣2,3 or ␣2,6 linkages. Therefore, the binding specificity of Siglec-10 seems similar to that of Siglec-5 (5), and 13) .
DISCUSSION
The Siglec-10 cDNA encodes a protein with many typical features of previously described Siglecs. The first Ig-like domain contains two amino acid residues critical in sialic acid recognition (22) : an arginine in ␤-strand F (Arg-119) and an aromatic amino acid in ␤-strand G (Phe-130). Crystallographic studies of Siglec-1/sialoadhesin have shown that these residues directly interact with the carboxyl group and glycerol-like side chain of sialic acid, respectively (22) . The high degree of sequence similarity with other Siglecs and the conservation of key residues implicated in sialic acid recognition increased the possibility that this protein was a new member of the Siglec family of IgSF proteins. We were able to show that full-length Siglec-10 expressed in COS cells behaved similarly to all other Siglecs thus far characterized in that it was able to bind human RBCs and soluble sialoglycoconjugates in a sialic-dependent manner. Therefore, Siglec-10 fulfills the criteria required for its inclusion in the Siglec subgroup of IgSF proteins (38) .
The cytoplasmic tail of Siglec-10 contains four tyrosine residues. It is of interest that Siglec-10 and other Siglecs share conserved tyrosine residues embedded in ITIM motifs that have been found in a growing number of cell surface members of the Ig family (39, 40) , although the location of motifs in Siglec-10 does not match the conserved positions in other Siglecs. In many cases, such ITIM motifs have been shown to be the docking site for the phosphotyrosine phosphatases (39, 41) and therefore could mediate negative regulatory signals via recruitment and activation of tyrosine phosphatases such as SHP-1, SHP-2, and SH2 domain-containing inositol phosphatase (39, 42) . The actual function of these motifs in Siglec-10 remains to be determined, but the motifs are likely to be involved in signal transduction, because those in Siglec-3/ CD33 and Siglec-7/AIRM1 have been shown to interact with SHP-1 (7, 26, 27) . It is also known that myelin-associated glycoprotein and CD22 mediate signaling by modulating the activity of protein tyrosine kinases (43) or phosphatases (44) via phosphotyrosine. The sequence around the second tyrosine of other Siglecs (TEYSEI in Siglec-5, -6, and -9), which does not strictly conform with but is similar to the proposed SAP-docking site (TIYXXV/I) on signaling lymphocytic-activating molecule/CDw150 (45) , is absent in Siglec-10. Future studies on the intracellular consensus motifs are needed and will facilitate understanding of the mechanisms of signaling functions of Siglecs.
Apart from myelin-associated glycoprotein, all currently known Siglecs (Fig. 2) have been found to be expressed in specific types of bone marrow stem cell-derived cells including B cells for CD22, myeloid progenitor cells for CD33, natural killer cells for Siglec-7, and eosinophils for Siglec-8. In fact, as analyzed by Northern blot analysis, Siglec-10 mRNA was found in relatively high abundance in peripheral blood leukocytes. RT-PCR revealed that Siglec-10 is actually expressed on DCs and monocytes. Thus DCs express several Siglecs simultaneously including Siglec-5, Siglec-7, and Siglec-10, and monocytes express CD33, Siglec-5, Siglec-7, and Siglec-10. We speculate that Siglec-10 is also predominantly expressed on some distinct populations of hematopoietic cells, playing roles in extracellular recognition and intercellular signaling, which is supported by the presence of ITIM-like motifs in its cytoplasmic region (see above). Experiments to analyze the hypotheti- cal role of Siglec-10 and that of another highly related Siglec, Siglec-5 (also on DCs and monocytes), is now underway in our laboratory.
It was of interest that when we searched the HTGS data base, the nucleotide sequence of Siglec-10 was found in chromosome 19 (working draft sequence AC008750 (data not shown)). These results along with published evidence for the presence of Siglec-3, -5, -6, -7, -8, and -9 genes on human chromosome 19q13.3-13.4 (5, 8 -10, 12, 13, 46, 47) indicated that there have been multiple gene duplications of the Siglec family genes during evolution from a common ancestral gene. Chromosome 19q13.3-13.4 is now recognized as a region that is especially enriched with a large number of other hematopoietically expressed Ig-related receptors described as the leukocyte receptor complex (48) . These include: a family of genes encoding Ig-like transcripts (ILT-1, -2, and -3) expressed on myeloid cells and subsets of lymphoid cells; killer cell inhibitory receptors expressed on natural killer cells and subsets of T cells; the gp49 family of receptors expressed on mast cells and natural killer cells; and the gene encoding human myeloid IgA Fc receptor (CD89) (49) . It has been suggested that these are involved in either activating or inhibitory signaling functions in hematopoietic cells (39) . Future studies are required to elucidate the putative functions of these sialic acid-binding receptors and to determine the full significance of sialic acid recognition.
